"BCG Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
Concept/Terms
BCG Vaccine- BCG Vaccine
- Vaccine, BCG
- Bacillus Calmette Guerin Vaccine
- Calmette Guerin Bacillus Vaccine
- Calmette's Vaccine
- Calmette Vaccine
- Calmettes Vaccine
- Vaccine, Calmette's
Below are MeSH descriptors whose meaning is more general than "BCG Vaccine".
Below are MeSH descriptors whose meaning is more specific than "BCG Vaccine".
This graph shows the total number of publications written about "BCG Vaccine" by people in Harvard Catalyst Profiles by year, and whether "BCG Vaccine" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 8 | 5 | 13 |
| 1996 | 4 | 2 | 6 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 2 | 3 |
| 2000 | 4 | 2 | 6 |
| 2001 | 2 | 2 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 5 | 2 | 7 |
| 2006 | 3 | 1 | 4 |
| 2007 | 7 | 1 | 8 |
| 2008 | 3 | 2 | 5 |
| 2009 | 4 | 0 | 4 |
| 2010 | 0 | 3 | 3 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 6 | 2 | 8 |
| 2014 | 4 | 2 | 6 |
| 2015 | 2 | 4 | 6 |
| 2016 | 1 | 2 | 3 |
| 2017 | 8 | 4 | 12 |
| 2018 | 9 | 2 | 11 |
| 2019 | 3 | 3 | 6 |
| 2020 | 6 | 3 | 9 |
| 2021 | 13 | 4 | 17 |
| 2022 | 2 | 9 | 11 |
| 2023 | 2 | 10 | 12 |
| 2024 | 1 | 0 | 1 |
Below are the most recent publications written about "BCG Vaccine" by people in Profiles.
-
Modelling the health and economic impacts ofM72/AS01E vaccination and BCG-revaccination: Estimates for South Africa. Vaccine. 2024 Feb 27; 42(6):1311-1318.
-
Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Cancer Med. 2023 12; 12(24):21944-21968.
-
Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer. Urol Oncol. 2024 Feb; 42(2):29.e17-29.e22.
-
Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer. JAMA Oncol. 2023 Nov 01; 9(11):1491-1492.
-
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol Oncol. 2023 Nov; 41(11):458.e1-458.e7.
-
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child Adolesc Health. 2023 10; 7(10):708-717.
-
New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01E and BCG-revaccination. BMC Med. 2023 08 04; 21(1):288.
-
Airway T cells are a correlate of i.v. Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques. Cell Host Microbe. 2023 06 14; 31(6):962-977.e8.
-
Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non-Muscle-Invasive Bladder Cancer. JAMA Netw Open. 2023 05 01; 6(5):e2314336.
-
The MotoNet: A 3 Tesla MRI-Conditional EEG Net with Embedded Motion Sensors. Sensors (Basel). 2023 Mar 28; 23(7).